Loading…
← CockpitCompetitor Analysis › STLN Oncology Institute, Inc.Open in the cockpit ↗

Oncology Institute, Inc.STLNCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services
Mkt cap
$326M
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$20.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-63.0 pp
WACC 7.0%
Hurdle
-16 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · USD$3.20
1D-5.9%
1W-23.8%
1M-51.7%
3M-51.1%
6Mn/a
YTDn/a
1Yn/a
ATR %17.0%
52w lowhigh55.1% off high

What Oncology Institute does

Employees: 641

Oncology Institute at a glance

Size Oncology Institute (STLN) is a United States Health Care company (Medical/Nursing Services) with a market value of $326M, the 3007th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.20 on 18 Nov 2026.

Growth Revenue grew 34.6% over the last twelve months (peer median +5.1%); the operating margin is -3.3% (peer median 8.4%).

Valuation It trades at 0.6× enterprise value to sales against a peer median of 1.9× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -16 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 63.0 points below its cost of capital (7.0% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Oncology Institute financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$620M$503M$393M$324M$252M
Revenue growth—+28%+21%+28%—
Gross profit$97.3M$69.5M$47.7M$53.7M$47.7M
EBITDA-$13.6M-$29.1M-$53.8M-$54.2M-$66.8M
Net income-$30.1M-$50.3M-$53.0M-$67.9M$132,000
Free cash flow$18.8M-$27.8M-$30.3M-$40.9M-$67.3M
Capital expenditure$4.27M$3.20M$3.79M$4.57M$5.53M
Total debt$103M$104M$123M$120M$108M

Quarterly statements and history in the cockpit →

Oncology Institute competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%2×4×6×NIOX300642AUNA3218AYUPADRAGARWQM129860JSLLIDXACL127120301060DNAWELLNEPHROPLUS1951STLNRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Oncology Institute is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%NIOX300642AUNA3218AYUPADRAGARWQM129860JSLLACL301060WELLNEPHROPLUSGMRS1951STLNGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Oncology Institute is the large dot.

Oncology Institute competitors and peer comparison

How Oncology Institute compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Oncology Institute against its 20 peers (data as of 18 Nov 2026)
MeasureSTLNPeer medianRank in peer set
1-month return-51.7%-6.8%lowest of 21
Distance from 52-week high-55.1%-26.3%3rd lowest of 21
Revenue growth (TTM)+34.6%+5.1%3rd highest of 21
Operating margin-3.3%8.4%5th lowest of 21
EV / Sales0.6×1.9×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)5.4%6.6%8th least demanding of 17
Growth delivered (Del g)+21.8%+15.4%6th highest of 17
Hurdle (Req g minus delivered)-16.4 pp-10.9 pp7th least demanding of 17
ROIC minus cost of capital-63.0 pp-0.3 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Oncology Institute STLNUnited States$326Mn/a+35%-3%0.6×5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%4.9×3.4%+15.3%
Tellgen 300642.SZChina$328M-11%+5%8%5.2×18.8%-5.8%
Auna AUNAUnited States$309M-5%+17%13%1.0×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%2.4×-13.8%+15.4%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%0.4×-14.9%+9.6%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%5.5×19.6%+27.5%
M1 Kliniken M12.DEGermany$368M+1%-28%13%1.2×-5.3%+17.9%
ADICON 9860.HKHong Kong$393M+5%+1%4%1.3×12.3%-1.5%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%4.0×7.3%+42.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%1.5×7.8%+17.7%
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%1.3×4.3%+2.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%1.4×n/an/a
JS Link 127120.KSSouth Korea$458M-62%+39%-83%25.2×n/an/a
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%2.3×5.9%+3.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%6.5×n/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%1.2×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%1.2×n/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%5.6×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%0.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%2.8×17.8%+12.4%

Questions

Which companies are Oncology Institute's closest peers?
The cockpit's peer set: NIOX (NIOX.L), Tellgen (300642.SZ), Auna (AUNA), Universal Vision Biotechnology (3218.TWO), Australian Unity Ltd Pref (AYUPA.AX), Dr. Agarwal'S Eye Hospital (DRAGARWQ.NS), M1 Kliniken (M12.DE), ADICON (9860.HK).
Is Oncology Institute expensive compared with its peers?
On ev / sales it trades at 0.6× against a peer median of 1.9×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -16 pp: the price already allows for a slowdown.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.